Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancers

Cancer Discovery
Judith BalmañaJudy E Garber

Abstract

The popular vision for the future of oncology includes the rational design of therapies inhibiting specific targets, for which development would be less expensive and the chance of success greater because the agent, the target, and a population predicted to benefit maximally would be known from the outset. In the breast cancer arena, successful targeted therapies have entered clinical practice. Recently, patients with BRCA-associated cancers have been identified as eligible for novel investigational therapies targeting their genetic deficiency. Preclinical data, phase I results, and 2 phase II proof-of-concept studies support the continued development of PARP inhibitors, either as single agents or in combination with specific cytotoxic drugs in this setting. In this article, we provide a brief review of current developments concerning PARP inhibitors in BRCA-associated cancers and express concerns about challenges to further development. PARP inhibitors may represent a new and promising targeted therapy for patients with BRCA1/2 -associated cancer. In this review we summarize the main challenges in the clinical development of these agents.

References

Aug 16, 2002·The New England Journal of Medicine·George D DemetriHeikki Joensuu
Jun 6, 2003·The New England Journal of Medicine·Richard Wooster, Barbara L Weber
Jun 26, 2009·The New England Journal of Medicine·Peter C FongJohann S de Bono
Jun 25, 2010·The New England Journal of Medicine·Makoto MaemondoUNKNOWN North-East Japan Study Group
Sep 8, 2010·The New England Journal of Medicine·Keith T FlahertyPaul B Chapman
Oct 29, 2010·The New England Journal of Medicine·Eunice L KwakA John Iafrate
Jan 7, 2011·The New England Journal of Medicine·Joyce O'ShaughnessyCharles Bradley

❮ Previous
Next ❯

Citations

Nov 10, 2013·Nature Medicine·Christopher J Lord, Alan Ashworth
Dec 24, 2015·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Sandrina LambrechtsIgnace Vergote
Dec 2, 2014·Breast Cancer Research : BCR·Hatem A Azim, Ann H Partridge
Nov 21, 2013·Journal of Experimental & Clinical Cancer Research : CR·Maria Saveria Gilardini MontaniSilvia Soddu
Jan 28, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Ji ZhangFang-Zhou Song
Jul 23, 2014·Breast Cancer Research and Treatment·Aleix PratJudith Balmaña
Jul 30, 2014·Asian Pacific Journal of Tropical Medicine·Xu ZhaoJia-Jun Yin
Aug 23, 2016·Gastroenterology Clinics of North America·Elena M Stoffel
Aug 17, 2016·Endocrine-related Cancer·Kiranjit K DhillonChristopher J Lord
Jan 23, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Zsofia K StadlerKenneth Offit
Jan 20, 2012·Nature·Christopher J Lord, Alan Ashworth
May 17, 2018·Breast Cancer Research and Treatment·Eugenia Fraile-BethencourtEladio A Velasco
Jun 21, 2019·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J MateoJ S de Bono
Jun 18, 2016·Oncology Nursing Forum·Meghan L UnderhillKarleen Habin
Jun 10, 2018·Current Oncology Reports·Narjust DumaCiara C O'Sullivan
Jun 21, 2020·International Journal of Molecular Sciences·Iris Z UrasEmilio Casanova
Nov 14, 2012·Cancer Discovery·Farah L RehmanAlan Ashworth
Jul 25, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yuqiao ShenAlan Ashworth
Jan 29, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J MateoJ S de Bono

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Related Papers

Expert Opinion on Investigational Drugs
Claudia MarchettiPierluigi Benedetti Panici
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Peter C FongStan B Kaye
The New England Journal of Medicine
Jonathan LedermannUrsula Matulonis
© 2021 Meta ULC. All rights reserved